Thomas A. Collet
Fondatore presso Phrixus Pharmaceuticals, Inc.
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Bruce Edward Markham | M | - |
Phrixus Pharmaceuticals, Inc.
 Phrixus Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Phrixus Pharmaceuticals, Inc. develops Carmeseal for DMD and for acute decompensated heart failure. It is repurposing Poloxamer for heart failure for which the only cure is heart transplantation. The company was founded by Thomas A. Collet and Bruce Markham in 2006 and is headquartered in Ann Arbor, MI. | 18 anni |
| Leslie J. Browne | M | 74 |
Phrixus Pharmaceuticals, Inc.
Phrixus Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Phrixus Pharmaceuticals, Inc. develops Carmeseal for DMD and for acute decompensated heart failure. It is repurposing Poloxamer for heart failure for which the only cure is heart transplantation. The company was founded by Thomas A. Collet and Bruce Markham in 2006 and is headquartered in Ann Arbor, MI. | 16 anni |
| Joshua Korzenik | M | - |
Bilayer Therapeutics, Inc.
 Bilayer Therapeutics, Inc. BiotechnologyHealth Technology Bilayer Therapeutics, Inc. is an American company that develops drugs for chronic disorders. The company was founded in 2020. The CEO is Thomas A. Collet. | - |
| Robert Langer | M | 74 |
Bilayer Therapeutics, Inc.
Bilayer Therapeutics, Inc. BiotechnologyHealth Technology Bilayer Therapeutics, Inc. is an American company that develops drugs for chronic disorders. The company was founded in 2020. The CEO is Thomas A. Collet. | - |
| Gerald D. Brennan | M | 73 |
Phrixus Pharmaceuticals, Inc.
Phrixus Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Phrixus Pharmaceuticals, Inc. develops Carmeseal for DMD and for acute decompensated heart failure. It is repurposing Poloxamer for heart failure for which the only cure is heart transplantation. The company was founded by Thomas A. Collet and Bruce Markham in 2006 and is headquartered in Ann Arbor, MI. | - |
| James Symons | M | - |
Phrixus Pharmaceuticals, Inc.
Phrixus Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Phrixus Pharmaceuticals, Inc. develops Carmeseal for DMD and for acute decompensated heart failure. It is repurposing Poloxamer for heart failure for which the only cure is heart transplantation. The company was founded by Thomas A. Collet and Bruce Markham in 2006 and is headquartered in Ann Arbor, MI. | - |
| David Zhu | M | - |
Bilayer Therapeutics, Inc.
Bilayer Therapeutics, Inc. BiotechnologyHealth Technology Bilayer Therapeutics, Inc. is an American company that develops drugs for chronic disorders. The company was founded in 2020. The CEO is Thomas A. Collet. | - |
| Joseph Metzger | M | - |
Phrixus Pharmaceuticals, Inc.
Phrixus Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Phrixus Pharmaceuticals, Inc. develops Carmeseal for DMD and for acute decompensated heart failure. It is repurposing Poloxamer for heart failure for which the only cure is heart transplantation. The company was founded by Thomas A. Collet and Bruce Markham in 2006 and is headquartered in Ann Arbor, MI. | - |
| Carlo Giovanni | M | - |
Bilayer Therapeutics, Inc.
Bilayer Therapeutics, Inc. BiotechnologyHealth Technology Bilayer Therapeutics, Inc. is an American company that develops drugs for chronic disorders. The company was founded in 2020. The CEO is Thomas A. Collet. | - |
| Yen Chen Huang | M | - |
Bilayer Therapeutics, Inc.
Bilayer Therapeutics, Inc. BiotechnologyHealth Technology Bilayer Therapeutics, Inc. is an American company that develops drugs for chronic disorders. The company was founded in 2020. The CEO is Thomas A. Collet. | - |
Grafico relazionale
Relazione in diverse aziende
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Stati Uniti | 10 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Thomas A. Collet
- Contatti personali
